862 related articles for article (PubMed ID: 25681684)
1. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
2. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitizing effects of metformin on cisplatin- and paclitaxel-resistant ovarian cancer cell lines.
Dos Santos Guimarães I; Ladislau-Magescky T; Tessarollo NG; Dos Santos DZ; Gimba ERP; Sternberg C; Silva IV; Rangel LBA
Pharmacol Rep; 2018 Jun; 70(3):409-417. PubMed ID: 29627688
[TBL] [Abstract][Full Text] [Related]
4. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.
Huang JM; Zhang GN; Shi Y; Zha X; Zhu Y; Wang MM; Lin Q; Wang W; Lu HY; Ma SQ; Cheng J; Deng BF
Sci Rep; 2014 Jan; 4():3840. PubMed ID: 24452475
[TBL] [Abstract][Full Text] [Related]
5. SMIFH2-mediated mDia formin functional inhibition potentiates chemotherapeutic targeting of human ovarian cancer spheroids.
Ziske MA; Pettee KM; Khaing M; Rubinic K; Eisenmann KM
Biochem Biophys Res Commun; 2016 Mar; 472(1):33-9. PubMed ID: 26898799
[TBL] [Abstract][Full Text] [Related]
6. IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells.
Singh RK; Gaikwad SM; Jinager A; Chaudhury S; Maheshwari A; Ray P
Cancer Lett; 2014 Nov; 354(2):254-62. PubMed ID: 25157649
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment.
Craveiro V; Yang-Hartwich Y; Holmberg JC; Joo WD; Sumi NJ; Pizzonia J; Griffin B; Gill SK; Silasi DA; Azodi M; Rutherford T; Alvero AB; Mor G
Cancer Med; 2013 Dec; 2(6):751-62. PubMed ID: 24403249
[TBL] [Abstract][Full Text] [Related]
8. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
9. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
10. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
Sun NK; Huang SL; Chang TC; Chao CC
J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
[TBL] [Abstract][Full Text] [Related]
11. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
12. The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins.
Li Z; Block MS; Vierkant RA; Fogarty ZC; Winham SJ; Visscher DW; Kalli KR; Wang C; Goode EL
Tumour Biol; 2016 Oct; 37(10):13279-13286. PubMed ID: 27460076
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel-exposed ovarian cancer cells induce cancer‑specific CD4+ T cells after doxorubicin exposure through regulation of MyD88 expression.
Kim JE; Jang MJ; Jin DH; Chung YH; Choi BS; Park GB; Kim YS; Kim S; Hur DY; Hung CF; Kim D
Int J Oncol; 2014 May; 44(5):1716-26. PubMed ID: 24573741
[TBL] [Abstract][Full Text] [Related]
14. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
[TBL] [Abstract][Full Text] [Related]
15. FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.
Liu YK; Jia YJ; Liu SH; Ma J
Cancer Chemother Pharmacol; 2021 Mar; 87(3):405-414. PubMed ID: 33392640
[TBL] [Abstract][Full Text] [Related]
16. p62/SQSTM1 as an oncotarget mediates cisplatin resistance through activating RIP1-NF-κB pathway in human ovarian cancer cells.
Yan XY; Zhang Y; Zhang JJ; Zhang LC; Liu YN; Wu Y; Xue YN; Lu SY; Su J; Sun LK
Cancer Sci; 2017 Jul; 108(7):1405-1413. PubMed ID: 28498503
[TBL] [Abstract][Full Text] [Related]
17. [Role and mechanism of the regulation of nuclear factor-κB by heparin binding-epidermal growth factor-like growth factor in the induction of paclitaxel resistance of ovarian cancer].
Tang XH; Lu MS; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2019 Apr; 54(4):255-261. PubMed ID: 31006192
[No Abstract] [Full Text] [Related]
18. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
[TBL] [Abstract][Full Text] [Related]
19. Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis.
Wei H; Hellström KE; Hellström I
Gynecol Oncol; 2012 Jun; 125(3):727-33. PubMed ID: 22430613
[TBL] [Abstract][Full Text] [Related]
20. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells.
Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H
Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
